39512-50-0

Basic information

• Product Name: 1-(2-Chlorophenyl)piperazine
• Synonyms: TIMTEC-BB SBB003581;1-(2-CHLORPHENYL)-PIPERAZINE;1-(2-CHLOROPHENYL)PIPERAZINE;AKOS BBS-00006438;LABOTEST-BB LT00077031;1-(2-Chlorophenyl)piperazine 98%;1-(2-CHLOROPHENYL)PIPERAZINE 98+%;1-(o-Chlorophenyl)piperazine
• CAS NO: 39512-50-0
• Molecular Formula: C₁₀H₁₃ClN₂
• Molecular Weight: 196.68
• EINECS: 254-480-3
• Product Categories: Piperidines, Piperidones, Piperazines;Piperazines
• Mol File: 39512-50-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 152-154 °C
• Boiling Point: 102-104°C 0,2mm
• Flash Point: 145.7 °C
• Appearance: white to yellow crystalline mass or oil
• Density: 1.18
• Vapor Pressure: 0.000387mmHg at 25°C
• Refractive Index: 1.5810-1.5850
• PKA: 8.81±0.10(Predicted)
• CAS DataBase Reference: 1-(2-Chlorophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Chlorophenyl)piperazine(39512-50-0)
• EPA Substance Registry System: 1-(2-Chlorophenyl)piperazine(39512-50-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 39512-50-0(Hazardous Substances Data)

Usage

Chemical Properties

white to yellow crystalline mass or oil

Uses

1-(2-Chlorophenyl)piperazine is a piperazine derivative useful in the treatment of cardiovascular and cerebrovascular diseases.

InChI:InChI=1/C10H13ClN2/c11-9-3-1-2-4-10(9)13-7-5-12-6-8-13/h1-4,12H,5-8H2/p+1

Upstream product

• 111-42-2 2,2'-iminobis[ethanol] 
• 95-51-2 o-chloroaniline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 110-85-0 piperazine 
• 95-50-1 1,2-dichloro-benzene 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 348-51-6 1-chloro-2-fluorobenzene 
• 694-80-4 2-bromo-1-chlorobenzene 
• 41202-32-8 1-(2-chlorophenyl)piperazine hydrochloride 

Downstream Products

• 40004-62-4 1-(2-hydroxyethyl)-4-(2-chlorophenyl)piperazine 
• 1047-41-2 1-[4-(2-chloro-phenyl)-piperazin-1-yl]-3-phenoxy-propan-2-ol 
• 110148-32-8 1-[4-(2-chloro-phenyl)-piperazino]-3-o-tolyloxy-propan-2-ol 
• 90125-89-6 1-(2-Chloro-phenyl)-4-(2-pyridin-2-yl-ethyl)-piperazine; compound with (Z)-but-2-enedioic acid 
• 1026587-21-2 1-Chloro-3-[4-(2-chloro-phenyl)-piperazin-1-yl]-propan-2-ol 
• 63377-89-9 1-(2-chlorophenyl)-4-(2-chloroethyl)-piperazine 
• 164071-36-7 2-{3-[4-(2-Chloro-phenyl)-piperazin-1-yl]-propyl}-3,7-dimethyl-5-piperidin-1-yl-2,3-dihydro-pyrido[3,4-d]pyridazine-1,4-dione 
• 185223-24-9 (1-Aza-bicyclo[2.2.2]oct-2-yl)-[4-(2-chloro-phenyl)-piperazin-1-yl]-methanone 

Relevant articles and documents

Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis

A safer treatment for toxoplasmosis would be achieved by improving the selectivity and potency of dihydrofolate reductase (DHFR) inhibitors, such as pyrimethamine (1), for Toxoplasma gondii DHFR (TgDHFR) relative to human DHFR (hDHFR). We previously reported on the identification of meta-biphenyl analog 2, designed by in silico modeling of key differences in the binding pocket between TgDHFR and hDHFR. Compound 2 improves TgDHFR selectivity 6.6-fold and potency 16-fold relative to 1. Here, we report on the optimization and structure-activity relationships of this arylpiperazine series leading to the discovery of 5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 3. Compound 3 has a TgDHFR IC50 of 1.57 ± 0.11 nM and a hDHFR to TgDHFR selectivity ratio of 196, making it 89-fold more potent and 16-fold more selective than 1. Compound 3 was highly effective in control of acute infection by highly virulent strains of T. gondii in the murine model, and it possesses the best combination of selectivity, potency, and prerequisite drug-like properties to advance into IND-enabling, preclinical development.

Preparation method of diaryl sulfide amine compound

The invention relates to a preparation method for a diaryl thioether amine compound. Specifically, the invention relates to a preparation method for 1-[2-(2,4-dimethylphenylsulfalkyl)phenyl]piperazine derivative as shown in a formula I which is described in the specification. The preparation method comprises the following steps: subjecting a compound as shown in a formula V and a compound as shown in a formula IV to cyclization, condensation or introduction of an amino protective group; carrying out further condensation; etc. Thus, the target compound is obtained. Compared with other methods, the preparation method provided by the invention has the advantages of good process reproducibility and easy operation and the characteristics of high yield, low cost and high product purity, is more suitable for industrial production and has higher economic benefits.

Chrysin-piperazine conjugates as antioxidant and anticancer agents

Synthesis of 7-(4-bromobutoxy)-5-hydroxy-2-phenyl-4H-chromen-4-one intermediate treating chrysin with 1,4-dibromobutane facilitated combination of chrysin with a wide range of piperazine moieties which were equipped via reacting the corresponding amines with bis(2-chloroethyl)amine hydrochloride in diethylene glycol monomethyl ether solvent. Free radical scavenging potential of prepared products was analyzed in vitro adopting DPPH and ABTS bioassay in addition to the evaluation of in vitro anticancer efficacies against cervical cancer cell lines (HeLa and CaSki) and an ovarian cancer cell line SK-OV-3 using SRB assay. Bearable toxicity of 7a-w was examined employing Madin-Darby canine kidney (MDCK) cell line. In addition, cytotoxic nature of the presented compounds was inspected utilizing Human bone marrow derived mesenchymal stem cells (hBM-MSCs). Overall, 7a-w indicated remarkable antioxidant power in scavenging DPPH+ and ABTS++, particularly analogs 7f, 7j, 7k, 7l, 7n, 7q, 7v, 7w have shown promising free radical scavenging activity. Analogs 7j and 7o are identified to be highly active candidates against HeLa and CaSki cell lines, whereas 7h and 7l along with 7j proved to be very sensitive towards ovarian cancer cell line SKOV-3. None of the newly prepared scaffolds showed cytotoxic nature toward hBM-MSCs cells. From the structure-activity point of view, nature and position of the electron withdrawing and electron donating functional groups on the piperazine core may contribute to the anticipated antioxidant and anticancer action. Different spectroscopic techniques (FT-IR, 1H NMR, 13C NMR, Mass) and elemental analysis (CHN) were utilized to confirm the desired structure of final compounds.